Stocks · News reference
Galmed Pharmaceuticals Announces Results From Pre-Clinical Study Of Combination Of Aramchol And Xtandi For Prostatic Cancer; New Data Demonstrated That A Combination Of Aramchol With Enzalutamide Resulted In Three- To Four-Fold Increase In Cell Death Compared With Enzalutamide As A Single Agent
Xtandi (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Galmed Pharmaceuticals Announces Rebrand To Eocene And Nasdaq Ticker Change From GLMD To EOCN Effective September 10; Announces Termination Of Yorkville Standby Equity Purchase Agreement Effective September 8
Galmed Pharmaceuticals shares are trading higher after the company's subsidiary Colospan announced the completion of a feasibility study supporting the development of a novel intraoperative colon tissue quality assessment platform.
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times